Zachou et al. investigated whether autoantibodies against filamentous-actin and α-actinin could be used as predictors of response to treatment in patients with autoimmune hepatitis type 1 (AIH1). The researchers analyzed serum samples at baseline and after initiation of treatment in 86 patients with AIH1. Low levels of anti-α-actinin at baseline were found to be independent predictors of response, and the researchers conclude that serum levels of anti-α-actinin could be used to monitor treatment outcomes in patients with AIH1.